
- /
- Supported exchanges
- / US
- / MIRM.NASDAQ
Mirum Pharmaceuticals Inc (MIRM NASDAQ) stock market data APIs
Mirum Pharmaceuticals Inc Financial Data Overview
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Mirum Pharmaceuticals Inc data using free add-ons & libraries
Get Mirum Pharmaceuticals Inc Fundamental Data
Mirum Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 379 M
- EBITDA: -52 304 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-06
- EPS/Forecast: -0.48
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Mirum Pharmaceuticals Inc News

Mirum Gains 35% in 3 Months: How Should You Play the Stock?
Mirum Pharmaceuticals MIRM has delivered a stellar performance over the past three months. Shares of the company have rallied 35% compared with the industry’s rise of 6.9%. The stock has also outper...


Mirum Hits All-Time High - Is There More Upside Ahead?
(RTTNews) - Mirum Pharmaceuticals Inc. (MIRM) has kicked off the year with commercial growth and successful pipeline milestones, propelling its shares to an all-time high of $53. The company has thre...

Mirum Pharmaceuticals stock hits all-time high at $54.46
Mirum Pharmaceuticals Inc (NASDAQ:MIRM). stock has reached an all-time high, hitting $54.46, as investors continue to show confidence in the company’s performance. With a market capitalization of $...

Exploring 3 High Growth Tech Stocks In The US Market
The U.S. market is currently experiencing a mix of volatility and optimism, with investor sentiment being influenced by renewed tariff threats and record highs in major indices like the S&P 500 and Na...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.